Charles Schwab Investment Management Inc. Lowers Stake in Aligos Therapeutics, Inc. (NASDAQ:ALGS)

Charles Schwab Investment Management Inc. cut its position in Aligos Therapeutics, Inc. (NASDAQ:ALGS) by 61.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,980 shares of the company’s stock after selling 19,403 shares during the period. Charles Schwab Investment Management Inc. owned about 0.37% of Aligos Therapeutics worth $104,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Separately, Armistice Capital LLC raised its position in shares of Aligos Therapeutics by 5.3% during the second quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock valued at $2,540,000 after buying an additional 363,000 shares during the last quarter. Hedge funds and other institutional investors own 60.43% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $75.00 target price on shares of Aligos Therapeutics in a research note on Thursday, November 7th.

Aligos Therapeutics Price Performance

NASDAQ ALGS opened at $39.84 on Friday. Aligos Therapeutics, Inc. has a 1-year low of $6.76 and a 1-year high of $41.64. The business has a 50 day simple moving average of $18.92 and a two-hundred day simple moving average of $14.32. The stock has a market capitalization of $142.95 million, a PE ratio of -2.99 and a beta of 2.73.

Aligos Therapeutics (NASDAQ:ALGS) last posted its earnings results on Wednesday, November 6th. The company reported ($3.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.15) by ($0.92). Aligos Therapeutics had a negative net margin of 1,283.19% and a negative return on equity of 114.34%. The business had revenue of $1.27 million during the quarter, compared to analysts’ expectations of $1.00 million. During the same period last year, the business posted ($10.25) earnings per share. On average, analysts anticipate that Aligos Therapeutics, Inc. will post -10.36 EPS for the current fiscal year.

Aligos Therapeutics Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).